非霍奇金淋巴瘤后第二原发恶性肿瘤的发病率和时间趋势:一项瑞典人群研究
该研究基于瑞典癌症登记处1993至2014年确诊的32100例非霍奇金淋巴瘤患者,匹配普通人群对照并随访至2017年。结果显示患者实体瘤发生率较对照高40%(HR=1.4;95%CI 1.4-1.5),骨髓增生异常综合征/急性髓系白血病发生率高5倍(HR=5.2;95%CI 4.4-6.2);除滤泡性淋巴瘤的MDS/AML超额风险随时间减弱(趋势P=.012)外,超额风险整体保持稳定。
要点
- 非霍奇金淋巴瘤患者实体瘤风险较对照高40%(HR=1.4;95%CI 1.4-1.5)。
- MDS/AML风险较对照高5倍(HR=5.2;95%CI 4.4-6.2)。
- 滤泡性淋巴瘤的MDS/AML超额风险随时间减弱(趋势P=.012)。
核心结论
- 非霍奇金淋巴瘤幸存者实体瘤和血液系统恶性肿瘤风险均升高,尤其是MDS/AML。
- 研究期间超额风险整体保持稳定,提示当代治疗标准未改变第二原发恶性肿瘤风险。
- 滤泡性淋巴瘤患者MDS/AML发生率下降,可能与非化疗治疗使用增加有关。
研究设计与样本
- 基于瑞典癌症登记处识别1993至2014年非霍奇金淋巴瘤患者,从瑞典总人口登记处匹配对照。
- 匹配队列随访至2017年,共纳入32100例非霍奇金淋巴瘤患者。
- 通过链接瑞典淋巴瘤登记处按非霍奇金淋巴瘤亚型进行亚队列分析。
- 采用灵活参数生存模型估计患者与对照间第二原发恶性肿瘤的风险比(HR)及95%置信区间(CI)。
主要发现
- 32100例患者中观察到3619例实体瘤和217例MDS/AML。
- 实体瘤发生率较对照高40%(HR=1.4;95%CI 1.4-1.5)。
- MDS/AML发生率较对照高5倍(HR=5.2;95%CI 4.4-6.2)。
- 实体瘤和MDS/AML的总体超额风险在研究期间保持稳定。
- 滤泡性淋巴瘤的MDS/AML超额风险随时间减弱(趋势P=.012)。
关键数值与推荐
- 实体瘤:HR=1.4(95%CI 1.4-1.5),患者较对照升高40%。
- MDS/AML:HR=5.2(95%CI 4.4-6.2),患者较对照升高5倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Considering treatment changes and an improved prognosis of non-Hodgkin lymphoma (NHL) over time, knowledge regarding long-term health outcomes, including late effects of treatment, has become increasingly important. We report on time trends of second primary malignancies (SPMs) in Swedish NHL patients, encompassing the years before as well as after the introduction of anti-CD20 antibody therapy. We identified NHL patients in the Swedish Cancer Register 1993 to 2014 and matched comparators from the Swedish Total Population Register. The matched cohort was followed through 2017. By linking to the Swedish Lymphoma Register, subcohort analyses by NHL subtype were performed. Flexible parametric survival models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) of SPM among patients and comparators. Among 32 100 NHL patients, 3619 solid tumors and 217 myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) cases were observed, corresponding to a 40% higher rate of solid tumors (HRsolid tumors = 1.4; 95% CI, 1.4-1.5) and a 5-fold higher rate of MDS/AML (HRMDS/AML = 5.2; 95% CI, 4.4-6.2) than for comparators. Overall, the observed excess risks for solid tumors or MDS/AML remained stable over the study period, except for follicular lymphoma, where the excess rate of MDS/AML attenuated with time (P for trend = .012). We conclude that NHL survivors have an increased risk of both solid tumors and hematologic malignancies, in particular MDS/AML. Stable excess risks over time indicate that contemporary treatment standards are not associated with modified SPM risk. Encouragingly, decreasing rates of MDS/AML were noted among patients with follicular lymphoma, possibly due to the increasing use of nonchemotherapy-based treatments.
引用
- Joelsson J, Wästerlid T, Rosenquist R, et al. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Adv. 2022. PMID: 35042239. doi:10.1182/bloodadvances.2021006369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。